Endocrine Research Updates

For Medical Professionals

In seniors with diabetes, common disease complications respond well with SGLT2i
The latest study findings on the safety and efficacy of the SGLT-2i, ertugliflozin, offer strong assurance for use in managing diabetes in individuals at 65 years plus, and in others, without concerns for adverse effects on renal function.
Since up to 30% of patients with cancer experience insomnia, even years later, a team from Dana Farbar Cancer Institute has developed a stepwise approach to improve sleep and designed for ease of implementation in any practice setting.
Advances promise preservative-free, fast-acting inhaled insulin for diabetes.
Next Generation Soft-Mist Inhaled human Insulin and GLP-1RA are advancing for treatment of diabetes, and other hormone therapies are just beginning development.
Diabetes distress arises in patients overwhelmed with a chronic disease.
This often unrecognized response arises when individuals are overwhelmed when facing the responsibility of managing a chronic life-long disease. Thus, regular screening should become a routine aspect of diabetes patient care.
Heart failure and renal disease must be treated as a complication of diabetes.
Insights on FDA approvals, side effects of pain meds, and key study findings presented at the European Association for the Study of Diabetes annual meeting,
Patients with Cushing's disease should be monitored for diabetes.
Finally, a long-lasting, monthly injection of pasireotide promotes normalized urinary free cortisol levels and a shrinking or arresting of tumor growth in patients with Cushing’s disease.
GLP-1RAs offer excellent benefits for cardiovascular diabetes.
A new meta-analysis affirms improvements in cardiovascular, kidney and overall outcomes in patients given a GLP-1RA versus SGLT2i for management of type 2 diabetes. Even in those without established cardiovascular disease, significant benefits are achieved with glucagon-like peptide-1 receptor agonists.
Testosterone levels increase risk of nonalcoholic fatty liver disease.
Study findings suggest that elevated levels of androgens even in younger women may offer a clue to patients at increased risk of developing nonalcoholic fatty liver disease.
Diabetic gastroparesis affects one-third of those with long-term diabetes.
A new surgical procedure, a promising minimally invasive, endoscopic device, and new uses for established drugs offer relief from gastrointestinal symptoms of this common complication of diabetes.
When prescribing a psych med, patients should be referred for weight loss.
Regardless of the type of psychiatric medications taken, including antidepressants and antipsychotics, patients who enroll in a weight loss program achieve weight loss, similar to those not taking these medications. This is important progress for many individuals who fear weight gain when they take psychopharmacological medications.
Thyroid hormones play a significant role in onset of NAFLD.
Type 2 diabetes is not the only precursor to nonalcoholic fatty liver disease, patients with thyroid disease also appear at elevated risk.
Hypoparathyroidism is the last endocrine disorder treated with hormone therapy.
The standard of care for hypoparathyroidism has been calcium and vitamin D replacement, making it the last endocrine deficiency for which hormone replacement is the treatment of choice.
The poor prognosis for aggressive thyroid tumors may improve with new drugs.
Considerable progress in understanding the molecular basis of rare thyroid cancer cases has led to the introduction of new drugs that target specific genetic mutations, enabling personalized care and improved survival.
Patients need are met for greater flexibility in diabetes drug formulations.
FDA approvals lead to the introduction of new formulations of glucagon, insulin, and statin therapy for patients with diabetes and cardiovascular disease, fulfilling a precept of precision medicine.
Increased comorbidity of migraines with metabolic and endocrine diseases.
Considering the increased likelihood that patients with migraine may also have hypothyroidism, diabetes, metabolic syndrome, and obesity, elevates the prospect of better overall medical management and improved quality of life.
Cardiac events present a greater risk of death than a diagnosis of cancer.
As people survive longer with cancer, including thyroid and other endocrine-related types, they face the added risk of cardiovascular disease morbidity and mortality, requiring ongoing clinical vigilance.
Need to focus on prevention to reduce risks of heart disease and diabetes.
Clinical Practice Guidance refocuses attention to visceral fat vs BMI, and lipid fractions beyond LDL, among other key risk factors. Also, even older patients need to continue statin therapy to avoid cardiac events.
Gentle nudges offer doctors a better approach to encourage weight loss.
Researchers focus on seven healthy eating strategies available to clinicians to make your next discussion about body weight to be more productive and constructive, drawn from results of a meta-analysis.
Central hypothyroidism needs treatment with levothyroxine.
A combination of mifepristone and levothyroxine proves beneficial in controlling excess cortisol in patients with central hypothyroidism.
NAFLD is a common complication of poorly controlled type 2 diabetes.
Patients who attend structured weight loss programs appear most successful at reverseing NAFLD but cost and lack of insurance reimbursement remain prohibitive obstacles.
close X